Drugs in Development
All Data
Brightest Minds in the CDMO industry - From early Development to Commercial Manufacturing
Lead Product(s): Opicapone
Therapeutic Area: Neurology Product Name: Ongentys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Bial
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2020
Details:
The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2020
Details:
By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
